aTyr Pharma Q2 net loss narrows - ATYR News | RalliesaTyr Pharma Q2 net loss narrows
A
ATYR• Outlook
- Company expects FDA feedback on Phase 3 efzofitimod protocol by end-August 2026
- aTyr Pharma expects topline results from Phase 2 SSc-ILD study in Q1 2027
- Company projects annualized operating expenses to decrease by $13 million from Q4 2026
Overview
- US biotech firm posted Q2 net loss of $10.3 million vs. loss of $19.5 million a year ago
- Company announced 60% workforce reduction to focus on efzofitimod in ILD
- Ended Q2 2026 with $58.9 million cash, expects runway into late 2028
Result drivers
- Clinical milestones - Enrollment completed in Phase 2 EFZO-CONNECT study for SSc-ILD
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 or , 5 and no or
"strong buy"
"buy"
"hold"
"sell"
"strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"Wall Street's median 12-month price target for aTyr Pharma Inc is $3.50, about 597.2% above its August 6 closing price of $0.50
